Chinese approval for drug-eluting beads delayed
This article was originally published in Clinica
Executive Summary
The Chinese State FDA has delayed the approval of Biocompatibles International's DC Bead for the treatment of liver cancer. SciClone Pharmaceuticals, Biocompatibles' distribution partner for China, has been told by the agency that it must conduct a small local trial to supplement data obtained from a previous study of the drug-coated beads performed in Hong Kong. If the trial, which is planned to commence this quarter, is successful, Biocompatibles (Farnham, UK) expects to receive Chinese regulatory approval for DC Bead in the second half of 2010 – the firm had hoped to launch the product in China this year. DC Bead is approved in 40 countries worldwide, including the US, where it is marketed as LC Bead, and Europe.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?